Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 2
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) w…
Carcinoma, HepatocellularLiver Cell Carcinoma
Rutgers, The State University of New JerseyNCT05366829
Phase 1
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) mali…
Solid Tumor (Excluding CNS)Liver Cell CarcinomaMalignant Rhabdoid Tumor+7 more
Seattle Children's HospitalNCT07148050
Phase 1
INTERCEPT-GPC3: Interleukin-15 and -21 Armored Glypican-3 Specific Chimeric Antigen Receptor Expressing Autologous T-cells in Adults With GPC3-positive Solid Tumors
This Phase 1, open-label, non-randomized study will enroll adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors e…
Solid Tumor (Excluding CNS)Hepatocellular CarcinomaLiver Cell Carcinoma+3 more
Seattle Children's HospitalNCT07224568